Posts by: Mary Chapman

News

The Canadian province of Saskatchewan has joined that of Quebec in granting access to Spinraza (nusinersen) therapy to a wider range of people with spinal muscular atrophy (SMA), Biogen Canada announced in a ... Read more

March 8, 2019March 12, 2019

Spinraza Developer Disappointed with Canadian Agency’s Updated Recommendation

News

While the Canadian Association of Drugs and Technologies in Health (CADTH) recommended that the spinal muscular atrophy treatment Spinraza should be made available to a broader population of patients, it ... Read more

March 1, 2019March 8, 2019

China Approves SMA Treatment Spinraza for Most Patients

News

Spinraza (nusinersen) has been approved by China’s National Medical Product Administration (NMPA) for the treatment of the most common form of spinal muscular atrophy (SMA). Marketed by Biogen and ... Read more

February 25, 2019March 4, 2019

British MP Pushes to Make Spinraza Treatment Available for SMA Patients

News

Citing the deteriorating health of a child with spinal muscular atrophy (SMA), a member of the British Parliament is pressing for the treatment Spinraza to be available in England. The ... Read more

February 14, 2019February 18, 2019

Scotland Opens Spinraza to All SMA Patients Using Its Public Health System

News

Scotland has joined the growing roster of countries making the spinal muscular atrophy (SMA) therapy Spinraza available to patients at low or no cost through that country’s public health system. ... Read more

February 11, 2019

Patients, Family and Friends to Take Part in Variety of Rare Disease Day Events Worldwide

News

Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run ... Read more

January 30, 2019February 5, 2019

FDA Revising ‘Draft Guidance’ on Developing Treatments for Rare Diseases

News

The U.S. Food and Drug Administration (FDA) is updating its 2015 draft guidelines for drug discovery in rare diseases, with new guidance on natural history — how disorders such ... Read more

January 25, 2019February 4, 2019

New Online Patient Education Program on Gene and Cell Therapies Launched

News

The American Society of Gene and Cell Therapy (ASGCT) has unveiled a new online resource designed to keep patients, caregivers, and the public apprised of the latest in gene ... Read more

December 14, 2018January 3, 2019

Cure SMA Campaign Promotes Early Diagnosis and Treatment

News

The Cure SMA educational campaign is designed to equip parents and healthcare professionals with the tools needed to recognize motor delays in spinal muscular atrophy (SMA) patients early, allowing infants ... Read more

October 22, 2018October 26, 2018

Developers of SMA Therapy Spinraza to Be Honored with $3M Prize at ‘Oscars of Science’

News

Pharmacologist C. Frank Bennett, PhD, and biochemist Adrian R. Krainer, PhD, have been awarded a prestigious 2019 Breakthrough Prize in Life Sciences for their role in the development of ... Read more

Posts by: Mary Chapman

Mary Chapman

SMA Patients in Saskatchewan, Canada, Gain Wider Access to Spinraza

Spinraza Developer Disappointed with Canadian Agency’s Updated Recommendation

China Approves SMA Treatment Spinraza for Most Patients

British MP Pushes to Make Spinraza Treatment Available for SMA Patients

Scotland Opens Spinraza to All SMA Patients Using Its Public Health System

Patients, Family and Friends to Take Part in Variety of Rare Disease Day Events Worldwide

FDA Revising ‘Draft Guidance’ on Developing Treatments for Rare Diseases

New Online Patient Education Program on Gene and Cell Therapies Launched

Cure SMA Campaign Promotes Early Diagnosis and Treatment

Developers of SMA Therapy Spinraza to Be Honored with $3M Prize at ‘Oscars of Science’

Pin It on Pinterest